Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Share-based Compensation for 10 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 51.35% year-over-year to $1.0 million, compared with a TTM value of $4.8 million through Sep 2025, down 41.82%, and an annual FY2024 reading of $7.8 million, down 1.75% over the prior year.
  • Share-based Compensation was $1.0 million for Q3 2025 at Spero Therapeutics, up from $714000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.2 million in Q1 2022 and bottomed at $714000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $2.0 million, with a median of $2.0 million recorded in 2024.
  • The sharpest move saw Share-based Compensation soared 114.51% in 2021, then plummeted 66.21% in 2025.
  • Year by year, Share-based Compensation stood at $2.9 million in 2021, then dropped by 14.72% to $2.5 million in 2022, then decreased by 20.02% to $2.0 million in 2023, then fell by 24.74% to $1.5 million in 2024, then tumbled by 30.27% to $1.0 million in 2025.
  • Business Quant data shows Share-based Compensation for SPRO at $1.0 million in Q3 2025, $714000.0 in Q2 2025, and $1.6 million in Q1 2025.